[ad_1] ISLAMABAD: The Islamabad High Court (IHC) Saturday constituted a special bench to hear a petition seeking investigation into medical reports of former prime minister Muhammad Nawaz Sharif through a commission. A special bench, comprising Justice Aamer Farooq and Justice Mohsin Akhtar Kayani, will hear the plea on November 24. The main Al-Azizia and Avenfield…
[ad_1] Clovis Oncology (NASDAQ:CLVS) will release its earnings data before the market opens on Thursday, August 1st. Analysts expect Clovis Oncology to post earnings of ($1.70) per share for the quarter. Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter,…
[ad_1] Axcella Health Inc (NASDAQ:AXLA) Director David R. Epstein purchased 4,556 shares of the firm’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were bought at an average price of $8.76 per share, with a total value of $39,910.56. The purchase was disclosed in a filing with the Securities & Exchange…
[ad_1] Clovis Oncology (NASDAQ:CLVS)’s stock price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $10.60 and last traded at $10.69, with a volume of 3245 shares traded. The stock had previously closed at $11.07. Several brokerages have issued reports on CLVS. SunTrust Banks raised their target…
[ad_1] Axcella Health Inc (NASDAQ:AXLA) Director David R. Epstein purchased 4,556 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The stock was purchased at an average cost of $8.76 per share, for a total transaction of $39,910.56. The purchase was disclosed in a filing with the SEC, which is accessible through…
[ad_1] HC Wainwright reaffirmed their buy rating on shares of Clovis Oncology (NASDAQ:CLVS) in a research report released on Wednesday, July 3rd, Stock Target Advisor reports. “Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present…
[ad_1] Clovis Oncology (NASDAQ:CLVS)’s stock price dropped 5.9% on Friday . The stock traded as low as $11.23 and last traded at $10.89, approximately 85,920 shares were traded during mid-day trading. A decline of 96% from the average daily volume of 2,020,116 shares. The stock had previously closed at $11.57. A number of research firms…
[ad_1] Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Thursday, June 27th, ThisIsMoney.Co.Uk reports. A number of other equities research analysts also recently issued reports on the company. Deutsche Bank reduced their price target on from GBX 217 ($2.84) to GBX 175 ($2.29) and…
[ad_1] Clovis Oncology (NASDAQ:CLVS) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $11.34 and last traded at $11.34, with a volume of 1732319 shares trading hands. The stock had previously closed at $12.33. Several equities analysts recently issued reports on the company. HC Wainwright set…
[ad_1] Axcella Health Inc (NASDAQ:AXLA) Director David R. Epstein bought 14,500 shares of the stock in a transaction on Wednesday, June 26th. The stock was purchased at an average price of $9.57 per share, with a total value of $138,765.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which…